



T CELL TUNING MOLECULES THAT MODIFY THE IMMUNE RESPONSE TO CANCER CELLS

SUMMARY

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on *in vitro* studies to validate these potential immunomodulators and to conduct *in vivo* studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

REFERENCE NUMBER

E-117-2016

PRODUCT TYPE

- Therapeutics

COLLABORATION OPPORTUNITY

This invention is available for licensing and co-development.

CONTACT

Martha Lubet

NICHD - Eunice Kennedy Shriver National Institute on Child Health and Human Development
240-276-5508

Martha.Lubet@nih.gov

DESCRIPTION OF TECHNOLOGY

Researchers at NIH/NICHD have identified approximately 200 proteins as candidate molecules (leads) that “fine tune” T cell receptor (TCR) signaling. *Eunice Kennedy Shriver National Institute of Child Health and Human Development* (NICHD) seeks partners to collaborate on *in vitro* studies to validate these potential immunomodulators and to conduct *in vivo* studies in a murine cancer model to determine the effects of ligands (e.g. antibodies) to the proteins to determine their effect on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

POTENTIAL COMMERCIAL APPLICATIONS

Agents that modify the immune response to cancer cells could be used in conjunction with other immunomodulators or therapeutic agents, such as vaccines

INVENTOR(S)



Paul Love, J. Pinkhasov and Z. Li (all of NICHD)

DEVELOPMENT STAGE

- Discovery (Lead Identification)

PUBLICATIONS

Pending

PATENT STATUS

- Not Patented

THERAPEUTIC AREA

- Cancer/Neoplasm